The cluster of five EU funded Horizon Europe R&D projects aims to increase the sustainability of pharmaceutical products and exploit research synergies to boost the impact of its innovations. All five projects focus on the development of innovative green pharmaceutical manufacturing methods.
ENVIROMED and other sister projects, ETERNAL, IMPACTIVE, SusPharma and TransPharm, have joined forces to form a Green Pharma Horizon Projects Cluster and capitalize on synergistic development. The aim of this cluster of R&D projects is to increase the sustainability of pharmaceutical products and exploit research synergies to boost the impact of innovations.
Three working groups have been created: active pharmaceutical ingredient synthesis, pharmaceutical life cycle assessment and communication of key messages.
The first working group aims to research relevant methodological issues that include assumptions made in pharma life cycle assessment (LCA), such as the functional unit, system boundaries and life cycle impact assessment (LCIA) methods. It will also address LCA data quality and data availability.
The second working group, Green-Pharma API Synthesis, explores the synergies the projects can create by focusing on the synthesis of different active pharmaceutical ingredients.
Finally, the third group, collaborates on communication and dissemination activities by setting up two-way communication channels with target audiences in the technical community and the general public, and disseminating key messages that can have an impact on interested parties. This group has a plan in place for the next twelve months that will build collective communication assets and coordinate efforts in areas such as social media and participation in high-profile events.
Read more here:
Download the Cluster brochure here: